Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.61 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745593 | 1.00 | GRM4 (0.61) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL179782 | 1.00 | GRM4 (0.61) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL7707996 | 0.87 | GGT1 (0.50) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065224 | 0.83 | GGT1 (0.47) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065228 | 0.81 | GGT1 (0.48) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065225 | 0.79 | GGT1 (0.43) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL8687592 | 0.78 | GGT1 (0.65) | GGT1ARG1ARG2ALDH1A1BLM | |
| SCHEMBL9507610 | 0.78 | GGT1 (0.46) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5063485 | 0.77 | GRM4 (1.00) | GRM4ALDH1A1FDPSBLMTYMS | |
| SCHEMBL12434713 | 0.76 | GGT1 (0.52) | GRM4GGT1ARG1ARG2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118980703-A | Microcosmic scale mineral identification method | 四川省地质工程勘察院集团有限公司 | 2024-11-19 | — | — | CN | claimed |
| US-12076386-B2 | Vaccine candidates against Johne's disease | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-09-03 | — | — | US | claimed |
| CN-116529258-A | Interleukin-2-Fc fusion proteins and methods of use | 吉利德科学公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023097186-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| CN-122089091-A | Full-process management decision-making method, device and equipment for farms based on AI (advanced technology attachment) agent | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | disclosed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12584272-B2 | Saccharide fatty acid ester latex barrier coating compositions | CHEMSTONE, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| CN-121578390-A | Intelligent acquisition and processing method and device for coal body energy-gathering blasting electric method data | 常州大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | disclosed |
| WO-2002102768-A2 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | THE ROCKEFELLER UNIVERSITY (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-0914206-B1 | LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS | UNIV CARNEGIE MELLON (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0733036-A1 | ALPHA-QUATERNARY-ALPHA-AMINO ACIDS FOR USE AS CNS AGENTS | UNIVERSITY OF BRISTOL (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015940-A1 | ALPHA-QUATERNARY-ALPHA-AMINO ACIDS FOR USE AS CNS AGENTS | UNIVERSITY OF BRISTOL (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | GRM4 4254/4885GGT1 1947/4885ARG1 1396/4885 |
| US-12584272-B2 | Saccharide fatty acid ester latex barrier coating compositions | SCD, FASN, MGAM | GRM4 3755/4885GGT1 1813/4885ARG1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.